USFDA issues EIR to Medak facility of Suven Life Sciences

Gayathri Udyawar
/ Categories: Trending, Markets

Suven Life Sciences Limited received Establishment Inspection Report (EIR) from US drug regulator for its Pashamylaram, Medak facility.

The USFDA conducted the inspection in February 2018. The regulator certified that the manufacturing facility complies with the standards of Current Good Manufacturing Processes (cGMP). The company has filed 19 Drug Master Files and 5 ANDAs from this facility.

Suven Life Sciences is a bio-pharma company based in Hyderabad based. The company manufactures and supplies APIs (bulk drugs), intermediates and formulations under cGMP. It is a leading manufacturer under Contract Research and Manufacturing Services (CRAMS) and Drug Discovery and Development program.

Meanwhile at 14:55 hours, the stock of Suven Life Sciences was quoting Rs. 190.65 per share, up by 5.19 per cent on Monday.

 

Previous Article Amid rising input cost tyre makers hike prices
Next Article Metal stocks shine, index up from 61.8 per cent retracement support
Rate this article:
3.0

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

SEBI Registered Research Analyst Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INH000006396
Validity: Oct 05, 2018 - Perpetual

View Registration Certificate

SEBI Registered Investment Adviser Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INA000001142
Validity: Aug 19, 2019 - Perpetual

View Registration Certificate

Registered Address:
419-A, 4th floor, Arun Chambers,
Tardeo, Next to AC Market, Mumbai - 400 034.
Tel: +91 022-43476012/13/14/15 | Email: service@dsij.in
CIN No.: U22120MH2003PTC139276
GST No.: 27AACCR4303G1ZP
BASL Membership ID: 1346

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR

Disclaimer: "Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors"

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

Any act of copying, reproducing, or distributing the content whether wholly or in part, for any purpose without the permission of DSIJ is strictly prohibited and shall be deemed to be copyright infringement.

Disclosures | Terms & Condition | Privacy Statement | WhiteList